• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania.
【24h】

A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania.

机译：奥氮平治疗毛滴虫病的随机，双盲，安慰剂对照试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Trichotillomania has been considered as part of the obsessive-compulsive disorder spectrum; however, trichotillomania treatment with obsessive-compulsive disorder medications has largely been unsuccessful. OBJECTIVE: To determine whether a dopaminergic treatment as used in tics and Tourette's syndrome would be effective in trichotillomania. METHOD: Twenty-five participants with DSM-IV trichotillomania participated in a 12-week, randomized, double-blind, placebo-controlled trial of flexible-dose olanzapine for trichotillomania. Recruitment occurred between August 2001 and December 2005, and follow-up was completed in February 2006. The primary outcome measure was the Clinical Global Impressions-Improvement (CGI-I) scale, and secondary measures of efficacy included the Yale-Brown Obsessive Compulsive Scale for Trichotillomania (TTM-YBOCS) and the Clinical Global Impressions-Severity of Illness (CGI-S) scale. RESULTS: Eleven of 13 participants (85%) in the olanzapine group and 2 of 12 (17%) in the placebo group were considered responders according to the CGI-I (P = .001). There was a significant change from baseline to end point in the TTM-YBOCS (P < .01) and the CGI-S (P < .001). The mean +/- SD dose of olanzapine at end point was 10.8 +/- 5.7 mg/d. Twenty-one of 25 patients (84%) reported at least 1 adverse event, but no adverse events resulted in early withdrawal from the study. CONCLUSION: Olanzapine seems to be a safe and effective treatment for primary DSM-IV trichotillomania. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00182507.
机译：背景：滴虫病被认为是强迫症的一部分。然而，用强迫症药物治疗毛滴虫病在很大程度上是不成功的。目的：确定抽动和抽动秽语综合征中使用的多巴胺能疗法对毛滴虫病是否有效。方法：25名DSM-IV毛滴虫病参与者参加了一项为期12周，随机，双盲，安慰剂对照的柔性剂量奥氮平治疗毛滴虫病的试验。招募发生在2001年8月至2005年12月之间，并于2006年2月完成了随访。主要结果指标是临床总体印象改善（CGI-1）量表，有效性的次要指标包括耶鲁-布朗强迫症量表。毛滴虫病（TTM-YBOCS）和疾病的临床总体印象-严重程度（CGI-S）量表。结果：根据CGI-I，奥氮平组的13名参与者中有11名（85％），安慰剂组的12名参与者中有2名（17％）被认为是应答者（P = .001）。从基线到终点，TTM-YBOCS（P <.01）和CGI-S（P <.001）有显着变化。终点的奥氮平平均+/- SD剂量为10.8 +/- 5.7 mg / d。 25名患者中有21名（84％）报告了至少1次不良事件，但没有不良事件导致该研究提早退出研究。结论：奥氮平似乎是治疗原发性DSM-IV毛滴虫病的一种安全有效的方法。试验注册：clinicaltrials.gov标识符：NCT00182507。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号